134 related articles for article (PubMed ID: 36912484)
1. Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial.
Thyssen JP; Werfel T; Barbarot S; Hunter HJA; Pierce E; Sun L; Cirri L; Buchanan AS; Lu N; Wollenberg A
J Dermatolog Treat; 2023 Dec; 34(1):2190430. PubMed ID: 36912484
[TBL] [Abstract][Full Text] [Related]
2. Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.
Silverberg JI; Simpson EL; Wollenberg A; Bissonnette R; Kabashima K; DeLozier AM; Sun L; Cardillo T; Nunes FP; Reich K
JAMA Dermatol; 2021 Jun; 157(6):691-699. PubMed ID: 33978711
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7.
Silverberg JI; Simpson EL; Thyssen JP; Werfel T; Cardillo TE; Colvin S; Pierce E; Chen YF; Chen S; Eichenfield L
J Eur Acad Dermatol Venereol; 2023 May; 37(5):1036-1045. PubMed ID: 36514996
[TBL] [Abstract][Full Text] [Related]
4. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials.
Reich K; DeLozier AM; Nunes FP; Thyssen JP; Eichenfield LF; Wollenberg A; Ross Terres JA; Watts SD; Chen YF; Simpson EL; Silverberg JI
J Dermatolog Treat; 2022 May; 33(3):1521-1530. PubMed ID: 33222559
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3.
Reich K; Simpson E; Wollenberg A; Bissonnette R; Abe M; Cardillo T; Janes J; Sun L; Chen S; Silverberg JI
Br J Dermatol; 2023 Feb; 188(2):208-217. PubMed ID: 36763879
[TBL] [Abstract][Full Text] [Related]
6. Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies.
Buhl T; Rosmarin D; Serra-Baldrich E; Fernandez-Peñas P; Igarashi A; Konstantinou MP; Chen S; Lu N; Pierce E; Casillas M
Dermatol Ther (Heidelb); 2021 Jun; 11(3):971-982. PubMed ID: 33899152
[TBL] [Abstract][Full Text] [Related]
7. Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long-term efficacy and patient-reported outcomes.
Simpson E; Armstrong A; Boguniewicz M; Chiesa Fuxench ZC; Feely M; Pierce E; Sun L; Chen YF; Angle R; Silverberg JI
Dermatol Ther; 2022 Dec; 35(12):e15954. PubMed ID: 36270978
[TBL] [Abstract][Full Text] [Related]
8. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial.
Wollenberg A; Nakahara T; Maari C; Peris K; Lio P; Augustin M; Silverberg JI; Rueda MJ; DeLozier AM; Pierce E; Yang FE; Sun L; Ball S; Tauber M; Paul C
J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):1543-1552. PubMed ID: 33834521
[TBL] [Abstract][Full Text] [Related]
9. Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis.
Bieber T; Thyssen JP; Irvine AD; Tsunemi Y; Chen YF; Sun L; Schloebe A; Riedl E; Cork MJ
Clin Exp Dermatol; 2023 Jul; 48(8):881-888. PubMed ID: 37032446
[TBL] [Abstract][Full Text] [Related]
10. Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7.
Thyssen JP; Buhl T; Fernández-Peñas P; Kabashima K; Chen S; Lu N; DeLozier AM; Casillas M; Ständer S
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1599-1611. PubMed ID: 34275122
[TBL] [Abstract][Full Text] [Related]
11. Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis.
Thyssen JP; Bieber T; Kleyn CE; Nosbaum A; Grond S; Petto H; Riedl E; Wollenberg A
J Dermatolog Treat; 2023 Dec; 34(1):2216322. PubMed ID: 37345379
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS).
Torrelo A; Rewerska B; Galimberti M; Paller A; Yang CY; Prakash A; Zhu D; Pontes Filho MAG; Wu WS; Eichenfield LF
Br J Dermatol; 2023 Jul; 189(1):23-32. PubMed ID: 36999560
[TBL] [Abstract][Full Text] [Related]
13. Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trials.
Wollenberg A; Lio P; Kleyn E; Bissonnette R; Jose Rueda M; Casillas M; Chen YF; Lu N; Schloebe A; Simpson E
Eur J Dermatol; 2022 Jul; 32(4):522-529. PubMed ID: 36301752
[TBL] [Abstract][Full Text] [Related]
14. Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16.
Silverberg JI; Boguniewicz M; Waibel J; Weisman J; Strowd L; Sun L; Ding Y; Feely M; Nunes FP; Simpson EL
Dermatol Ther (Heidelb); 2022 Jan; 12(1):137-148. PubMed ID: 34846636
[TBL] [Abstract][Full Text] [Related]
15. Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysis from BREEZE-AD7.
Masuda K; Delozier AM; Kolodsick J; Buchanan A; Pink AE; Sun L; Wang Z; Stingeni L; Thac I D
Eur J Dermatol; 2022 Apr; 32(2):237-243. PubMed ID: 35866910
[TBL] [Abstract][Full Text] [Related]
16. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials.
Bieber T; Katoh N; Simpson EL; de Bruin-Weller M; Thaçi D; Torrelo A; Sontag A; Grond S; Issa M; Lu X; Cardillo T; Holzwarth K; Thyssen JP
J Dermatolog Treat; 2023 Dec; 34(1):2161812. PubMed ID: 36546346
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
Reich K; Kabashima K; Peris K; Silverberg JI; Eichenfield LF; Bieber T; Kaszuba A; Kolodsick J; Yang FE; Gamalo M; Brinker DR; DeLozier AM; Janes JM; Nunes FP; Thyssen JP; Simpson EL
JAMA Dermatol; 2020 Dec; 156(12):1333-1343. PubMed ID: 33001140
[TBL] [Abstract][Full Text] [Related]
18. Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores.
Wollenberg A; Simon D; Kulthanan K; Figueras-Nart I; Misery L; Tangsirisap N; Spina L; Lu N; Grond S; Eyerich K
J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):695-702. PubMed ID: 38041556
[TBL] [Abstract][Full Text] [Related]
19. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitis.
Simpson EL; Bissonnette R; Paller AS; King B; Silverberg JI; Reich K; Thyssen JP; Doll H; Sun L; DeLozier AM; Nunes FP; Eichenfield LF
Br J Dermatol; 2022 Oct; 187(4):531-538. PubMed ID: 35442530
[TBL] [Abstract][Full Text] [Related]
20. Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5).
Rosmarin D; Casillas M; Chen S; Dawson Z; Pierce E; Zhang H; Bukhalo M; Smith S
J Cutan Med Surg; 2022; 26(3):262-266. PubMed ID: 35086348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
